Show Stocks and Investing Publications • Tue, October 12, 2021
• Wed, October 13, 2021
Matthew Harrison Maintained (BIIB) at Buy with Decreased Target to $447 on, Oct 12th, 2021
on-maintained-biib-at-buy-with-decreased-target-to-447-on-oct-12th-2021.html
Stocks and Investing on Sun, Oct 27th, 2024Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $455 to $447 on, Oct 12th, 2021.
Matthew has made no other calls on BIIB in the last 4 months.
There are 10 other peers that have a rating on BIIB. Out of the 10 peers that are also analyzing BIIB, 4 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $290 on, Friday, October 8th, 2021
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $326 on, Wednesday, September 29th, 2021
- Salim Syed of "Mizuho" Maintained at Hold with Increased Target to $300 on, Monday, August 2nd, 2021
- Terence Flynn of "Goldman Sachs" Maintained at Hold with Increased Target to $436 on, Monday, June 14th, 2021
These are the ratings of the 6 analyists that currently disagree with Matthew
- Michael Yee of "Jefferies" Maintained at Strong Buy with Decreased Target to $400 on, Friday, October 8th, 2021
- Ami Fadia of "Needham" Initiated at Strong Buy and Held Target at $400 on, Thursday, September 23rd, 2021
- Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $442 on, Thursday, September 16th, 2021
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $423 on, Tuesday, July 27th, 2021
- Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $450 on, Friday, June 18th, 2021
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $647 on, Monday, June 14th, 2021